» Articles » PMID: 25207821

Age-dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: a Report from the Children's Oncology Group

Abstract

Prognostic effects of Mitosis-Karyorrhexis Index (MKI) used in the International Neuroblastoma Pathology Classification (INPC) are age-dependent. A total of 4,282 neuroblastomas reviewed at the Children's Oncology Group Neuroblastoma Pathology Reference Laboratory (8/1/2001-3/31/2012) included 2,365 low-MKI (L-MKI), 1,068 intermediate-MKI (I-MKI), and 849 high-MKI (H-MKI) tumors. Cox proportional hazards models were fit to determine age cut-offs at which the relative risk of event/death was maximized in each MKI class. Backward-selected Cox models were fit to determine the prognostic strength of the age cut-offs for survival in the presence of other prognostic factors. The age cut-offs used in the INPC for L-MKI tumors (<60 months, n  =  2,710, 84.0% ± 1.0% event-free survival [EFS], 93.8 ± 0.7% overall survival [OS] vs ≥60 months, n  =  195, 49.8% ± 4.6% EFS, 71.7% ± 4.1% OS; P < 0.0001) and I-MKI tumors (<18 months, n  =  568, 83.8% ± 2% EFS, 93.7% ± 1.3% OS vs ≥18 months, n  =  500, 51.4% ± 2.9% EFS, 66.7% ± 2.7% OS; P < 0.0001) were within the effective range for distinguishing prognostic groups. As for H-MKI tumors (no cut-off age in the INPC, 51.0% ± 2.2% EFS, 64.4% ± 2.1% OS), a new cut-off of 3-4 months was suggested (<4 months, n  =  38, 82.3% ± 8.4% EFS, 81.8% ± 8.5% OS vs ≥4 months, n  =  811, 49.6% ± 2.2% EFS, 63.7% ± 2.1% OS, P  =  0.0034 and 0.0437, respectively). Multivariate analyses revealed that cut-offs of 60 and 18 months for L-MKI and I-MKI tumors, respectively, were independently prognostic. However, the cut-off of 4 months for H-MKI tumors did not reach statistical significance in the presence of other factors. The age cut-offs for MKI classes (60 months for L-MKI, 18 months for I-MKI, no cut-off for H-MKI) in the current INPC are reasonable and effective for distinguishing prognostic groups with increased risk of event/death for older patients.

Citing Articles

The relationship between contrast-enhanced computed tomography radiomics features and mitosis karyorrhexis index in neuroblastoma.

Chen X, Wang H, Xia Y, Shi F, He L, Liu E Discov Oncol. 2024; 15(1):201.

PMID: 38822860 PMC: 11144178. DOI: 10.1007/s12672-024-01067-0.


Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.

Feng L, Kan Y, Wang W, Wang C, Zhang H, Xie P J Cancer Res Clin Oncol. 2023; 149(18):16377-16390.

PMID: 37702807 DOI: 10.1007/s00432-023-05398-3.


Analysis of sensitivity and specificity: precise recognition of neutrophils during regeneration of contused skeletal muscle in rats.

Niu J, An G, Gu Z, Li P, Liu Q, Bai R Forensic Sci Res. 2022; 7(2):228-237.

PMID: 35784418 PMC: 9245985. DOI: 10.1080/20961790.2020.1713432.


Prediction for Mitosis-Karyorrhexis Index Status of Pediatric Neuroblastoma via Machine Learning Based F-FDG PET/CT Radiomics.

Feng L, Qian L, Yang S, Ren Q, Zhang S, Qin H Diagnostics (Basel). 2022; 12(2).

PMID: 35204353 PMC: 8871335. DOI: 10.3390/diagnostics12020262.


Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.

Shimada H, Ikegaki N Biomolecules. 2022; 12(1).

PMID: 35053227 PMC: 8773700. DOI: 10.3390/biom12010079.


References
1.
Oppedal B, Lie S, Brandtzaeg P . Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer. 1988; 62(4):772-80. DOI: 10.1002/1097-0142(19880815)62:4<772::aid-cncr2820620422>3.0.co;2-u. View

2.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

3.
Look A, Hayes F, Nitschke R, MCWILLIAMS N, Green A . Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984; 311(4):231-5. DOI: 10.1056/NEJM198407263110405. View

4.
Mugrauer G, Alt F, Ekblom P . N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization. J Cell Biol. 1988; 107(4):1325-35. PMC: 2115249. DOI: 10.1083/jcb.107.4.1325. View

5.
Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S . Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35(1):1-39. PMC: 2025310. DOI: 10.1038/bjc.1977.1. View